Gilead Sciences Inc.
Daniel Patrick O'Day (Chairman & CEO) sells GILD shares
AI-generated summary
Daniel Patrick O'Day, Chairman & CEO, Director of Gilead Sciences Inc., exercised options for 112,429 shares of Common Stock for $8,133,113.86 and sold 112,429 shares of Common Stock for $19,693,438.81. After these transactions, the insider directly held 551,683 shares. The transactions were executed under a Rule 10b5-1 trading plan adopted on February 25, 2026.
Key facts
- Insider
- Daniel Patrick O'Day · Chairman & CEO, Director
Rule 10b5-1 plan · adopted Feb 25, 2026
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | M · exercise or conversion of a derivativeFootnotes F1 | +102,619 | $72.34 | $7,423,458.46 | 654,302 | Direct |
| Nov 4, 2026 | S · open-market saleFootnotes F1, F2 | −102,619 | $175.16 | $17,975,021.11 | 551,683 | Direct |
| Nov 5, 2026 | M · exercise or conversion of a derivativeFootnotes F1 | +9,810 | $72.34 | $709,655.40 | 561,493 | Direct |
| Nov 5, 2026 | S · open-market saleFootnotes F1 | −9,810 | $175.17 | $1,718,417.70 | 551,683 | Direct |
| Nov 4, 2026 | M · exercise or conversion of a derivativeNon-qualified Stock Option (Right to Buy)Footnotes F1, F3 | −102,619 | $0.00 | $0.00 | 138,120 | Direct |
| Nov 5, 2026 | M · exercise or conversion of a derivativeNon-qualified Stock Option (Right to Buy)Footnotes F1, F3 | −9,810 | $0.00 | $0.00 | 128,310 | Direct |
Footnotes
- F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.
- F2 Sale prices for the transactions reported range from $175.05 to $175.35. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
- F3 The stock options have a four-year vesting schedule. 25% of the stock options vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
More GILD filings
- 144
Filed Nov 6, 2026
- 144
Filed Nov 4, 2026
- 4
Filed Nov 2, 2026
- 144
Filed Oct 30, 2026
- 10-Q
Filed Oct 29, 2026
- 8-K
Filed Oct 29, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.